Maria W Greenwald

Summary

Country: USA

Publications

  1. ncbi request reprint Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects
    Maria W Greenwald
    Osteoporosis Medical Center, Annenberg Center for Health Sciences, Rancho Mirage, CA, USA
    Menopause 12:741-8. 2005
  2. doi request reprint Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial
    Maria W Greenwald
    Desert Medical Advances, Palm Desert, California 92260, USA
    Arthritis Rheum 63:622-32. 2011
  3. ncbi request reprint Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial
    Alan J Kivitz
    Altoona Center for Clinical Research, Duncansville, Pennsylvania, USA
    J Am Geriatr Soc 52:666-74. 2004
  4. ncbi request reprint Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus
    Michelle A Petri
    Johns Hopkins University Medical Center, Baltimore, Maryland 21205, USA
    Arthritis Rheum 50:2858-68. 2004
  5. ncbi request reprint Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    Stanley B Cohen
    Radiant Research, Dallas, Texas 75235, USA
    Arthritis Rheum 54:2793-806. 2006

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects
    Maria W Greenwald
    Osteoporosis Medical Center, Annenberg Center for Health Sciences, Rancho Mirage, CA, USA
    Menopause 12:741-8. 2005
    ....
  2. doi request reprint Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial
    Maria W Greenwald
    Desert Medical Advances, Palm Desert, California 92260, USA
    Arthritis Rheum 63:622-32. 2011
    ..To assess the safety of rituximab in combination with a tumor necrosis factor (TNF) inhibitor and methotrexate (MTX) in patients with rheumatoid arthritis (RA)...
  3. ncbi request reprint Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial
    Alan J Kivitz
    Altoona Center for Clinical Research, Duncansville, Pennsylvania, USA
    J Am Geriatr Soc 52:666-74. 2004
    ..To evaluate the use of starting doses of rofecoxib and nabumetone in patients with osteoarthritis (OA) of the knee...
  4. ncbi request reprint Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus
    Michelle A Petri
    Johns Hopkins University Medical Center, Baltimore, Maryland 21205, USA
    Arthritis Rheum 50:2858-68. 2004
    ..To determine whether prasterone administration results in improvement or stabilization of systemic lupus erythematosus (SLE) disease activity and its symptoms...
  5. ncbi request reprint Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    Stanley B Cohen
    Radiant Research, Dallas, Texas 75235, USA
    Arthritis Rheum 54:2793-806. 2006
    ....